Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    June 2017
  1. TODESCO E, Demeret S, Calin R, Roque-Afonso AM, et al
    Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS. 2017;31:1346-1348.
    PubMed     Text format    


  2. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    AIDS. 2017;31:1223-1234.
    PubMed     Text format     Abstract available


    May 2017
  3. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.
    AIDS. 2017;31:1099-1107.
    PubMed     Text format     Abstract available


  4. HOORNENBORG E, Achterbergh RCA, Schim Van Der Loeff MF, Davidovich U, et al
    Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study.
    AIDS. 2017 May 1. doi: 10.1097/QAD.0000000000001522.
    PubMed     Text format     Abstract available


    March 2017
  5. MONTES ML, Olveira A, Ahumada A, Aldamiz T, et al
    Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    AIDS. 2017 Mar 29. doi: 10.1097/QAD.0000000000001465.
    PubMed     Text format     Abstract available


  6. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001448.
    PubMed     Text format     Abstract available


  7. PRICE H, Dunn D, Zachary T, Vudriko T, et al
    Hepatitis B serological markers and plasma DNA concentrations: baseline results from the DART trial.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001454.
    PubMed     Text format     Abstract available


  8. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    HCV drives increased type I IFN-associated impairments associated to fibrosis severity in ART-treated HIV-1-HCV coinfected individuals.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001455.
    PubMed     Text format     Abstract available


  9. TOBIN SC
    Evaluating the generalizability of clinical trials of direct-acting antivirals for HIV/HCV-coinfection.
    AIDS. 2017 Mar 1. doi: 10.1097/QAD.0000000000001439.
    PubMed     Text format    


    January 2017
  10. REID M, Ma Y, Scherzer R, Price JC, et al
    Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
    AIDS. 2017;31:385-393.
    PubMed     Text format     Abstract available


  11. SORIANO V, Sherman KE, Barreiro P
    Hepatitis Delta and HIV Infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001424.
    PubMed     Text format     Abstract available


  12. PINATO DJ, Pria AD, Sharma R, Bower M, et al
    Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV co-infection.
    AIDS. 2017 Jan 24. doi: 10.1097/QAD.0000000000001422.
    PubMed     Text format     Abstract available


  13. SEREMBA E, Ssempijja V, Kalibbala S, Gray RH, et al
    Hepatitis B incidence and prevention with antiretroviral therapy among HIV positive individuals in Rakai, Uganda.
    AIDS. 2017 Jan 17. doi: 10.1097/QAD.0000000000001399.
    PubMed     Text format     Abstract available



  14. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe.
    AIDS. 2017;31:127-135.
    PubMed     Text format     Abstract available


  15. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Text format     Abstract available


    December 2016
  16. PETERS L, Cozzi-Lepri A
    Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?
    AIDS. 2016 Dec 21. doi: 10.1097/QAD.0000000000001378.
    PubMed     Text format     Abstract available


  17. MERCHANTE N, Rivero-Juarez A, Tellez F, Merino D, et al
    Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    October 2016
  18. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.
    AIDS. 2016;30:2469-2476.
    PubMed     Text format     Abstract available


    September 2016
  19. SCHERZER R, Heymsfield SB, Rimland D, Powderly WG, et al
    Association of serum albumin and AST with 5-year all-cause mortality in HIV/HCV coinfection and HIV monoinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  20. THORNE C, Turkova A, Indolfi G, Venturini E, et al
    Co-infection with HIV and HCV in 229 children and young adults living in Europe.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  21. NEWSUM AM, Ho CK, Lieveld FI, Van De Laar TJ, et al
    The hepatitis C virus NS3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    August 2016
  22. MILLARD JD, Henry J, Rizvi SS, Nelson M, et al
    Direct-acting antivirals for acute hepatitis C in HIV-infected MSM.
    AIDS. 2016;30:2137-9.
    PubMed     Text format    


  23. OLIVER NT, Hartman CM, Kramer JR, Chiao EY, et al
    Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  24. GOWDA C, Brown TT, Compher C, Forde KA, et al
    Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    July 2016
  25. CACHAY E, Soriano V
    Is HIV still a special population for the treatment of hepatitis C?
    AIDS. 2016;30:2001-3.
    PubMed     Text format    


  26. CHEW KW, Bhattacharya D
    Virologic and immunologic aspects of HIV-HCV coinfection.
    AIDS. 2016.
    PubMed     Text format     Abstract available


    June 2016
  27. HAGAN H, Jordan AE, Cleland CM
    Response to the calculation of population attributable fractions of risk factors for hepatitis C transmission: authors' reply.
    AIDS. 2016;30:1685.
    PubMed     Text format    


  28. SCHMIDT AJ, Bremer V
    Response to the calculation of population attributable fractions (PAFs) of risk factors for hepatitis C transmission.
    AIDS. 2016;30:1683-4.
    PubMed     Text format    


  29. SMOLDERS EJ, Kanter CT, Grintjes K, D'Avolio A, et al
    Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
    AIDS. 2016;30:1491-3.
    PubMed     Text format    


  30. GARCIA M, Le Moal G, Godet C, Beraud G, et al
    First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS. 2016;30:1487-8.
    PubMed     Text format    


    May 2016
  31. KHELOUFI F, Bellissant E, Cotte L, Poizot-Martin I, et al
    eGFR but not SLC polymorphisms influences anemia in HIV-HCV co-infected patients treated with boceprevir- or telaprevir-based therapy (ANRS HC26 and HC27 Study).
    AIDS. 2016.
    PubMed     Text format     Abstract available


    April 2016
  32. GARCIA-ALVAREZ M, Berenguer J, Jimenez-Sousa MA, Vazquez-Moron S, et al
    Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients.
    AIDS. 2016;30:1069-1074.
    PubMed     Text format     Abstract available


    February 2016
  33. ROSSI C, Cox J, Cooper C, Martel-Laferriere V, et al
    Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV co-infected patients.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  34. CHILDS K, Taylor C, Dieterich D, Agarwal K, et al
    Directly acting antivirals (DAAs) for HCV arrive in HIV/HCV co-infected patients: from 'mind the gap' to 'where's the gap?'
    AIDS. 2016.
    PubMed     Text format    


    January 2016
  35. BEGUELIN C, Vazquez M, Moradpour D, Sahli R, et al
    Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
    AIDS. 2016;30:530-3.
    PubMed     Text format    


  36. JIMENEZ-SOUSA MA, Berenguer J, Garcia-Alvarez M, Gutierrez-Rivas M, et al
    Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients.
    AIDS. 2016;30:465-70.
    PubMed     Text format     Abstract available


  37. MANDORFER M, Schwabl P, Steiner S, Scheiner B, et al
    Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease.
    AIDS. 2016.
    PubMed     Text format     Abstract available


  38. GRANT JL, Hawkins C, Brooks H, Palella FJ Jr, et al
    Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    AIDS. 2016;30:93-8.
    PubMed     Text format     Abstract available


  39. TOWNSEND K, Petersen T, Gordon LA, Kohli A, et al
    Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
    AIDS. 2016;30:261-6.
    PubMed     Text format     Abstract available


  40. FAGIUOLI S, Puoti M, Rizzardini G
    Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders?
    AIDS. 2016;30:323-5.
    PubMed     Text format    


  41. PARK LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, et al
    Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.
    AIDS. 2016;30:273-91.
    PubMed     Text format     Abstract available


    December 2015
  42. LIU L, Nardo D, Li E
    CD4+ T-cell recovery with suppressive ART induced rapid sequence evolution in HCV envelope but not NS3.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    November 2015
  43. PETERS MG, Bacchetti P, Boylan R, French AL, et al
    Enhanced liver fibrosis marker as a non-invasive predictor of mortality in HIV/HCV-coinfected women from the women's Interagency HIV study.
    AIDS. 2015.
    PubMed     Text format     Abstract available


    September 2015
  44. REAL LM, Herrero R, Rivero-Juarez A, Camacho A, et al
    IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
    AIDS. 2015;29:1895-7.
    PubMed     Text format     Abstract available


    June 2015
  45. THIO CL, Smeaton L, Hollabaugh K, Saulynas M, et al
    Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    AIDS. 2015;29:1173-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: